| wang, shusen |
SMART, NCT03561740: A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients |
|
|
| Recruiting | 3 | 794 | RoW | capecitabine, Xeloda | Sun Yat-sen University | Breast Cancer | 06/23 | 12/28 | | |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
MECCA, NCT02767661: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 240 | RoW | Capecitabine, xeloda, Aromatase Inhibitor, anastrozole, letrozole, exemestane | Sun Yat-sen University | Breast Cancer | 05/24 | 05/24 | | |
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 542 | RoW | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/27 | 12/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
NCT04263298: Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 210 | RoW | Fulvestrant, Experimental group, Capecitabine Oral Product, Active Comparator control group | Herui Yao | Metastatic Breast Cancer | 05/25 | 05/30 | | |
NCT05430399: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 349 | RoW | utidelone, docetaxel | Sun Yat-sen University, Beijing Biostar Pharmaceuticals Co., Ltd., Hunan Cancer Hospital | Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | 06/25 | 06/27 | | |
NCT02448576: PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy |
|
|
| Not yet recruiting | 3 | 326 | RoW | prophylactic cranial irradiation | wang shusen | Breast Cancer, Brain Metastasis | 08/25 | 08/25 | | |
BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer |
|
|
| Recruiting | 3 | 766 | RoW | Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist | Fudan University | Breast Cancer | 05/28 | 05/31 | | |
BCTOP-T-A03, NCT05909332: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients |
|
|
| Recruiting | 3 | 548 | RoW | Antivascular therapy, Chemotherapy | Fudan University | Breast Cancer, Triple Negative Breast Cancer | 05/29 | 05/31 | | |
OPTIMAL, NCT03315364: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy |
|
|
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 12/24 | 12/26 | | |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 11/24 | 12/24 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
Increase, NCT04941885: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer |
|
|
| Recruiting | 2 | 78 | RoW | Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI | Sun Yat-sen University | Breast Cancer | 07/23 | 07/25 | | |
SYSUCC-019, NCT05390476: Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial |
|
|
| Recruiting | 2 | 126 | RoW | Capecitabine, xeloda, Tucidinostat, Chidamide | wang shusen | Triple Negative Breast Cancer | 02/24 | 12/24 | | |
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC |
|
|
| Recruiting | 2 | 38 | RoW | Chiauranib, capecitabine | Chipscreen Biosciences, Ltd. | Triple-negative Breast Cancer | 12/24 | 12/24 | | |
NCT05411380: Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. |
|
|
| Recruiting | 2 | 73 | RoW | Tucidinostat, Chidamide, Capecitabine, Xeloda, Endocrine Therapy, Anastrozole, Letrozole, Exemestane, Fulvestrant | wang shusen | Breast Cancer | 04/24 | 04/25 | | |
NCT05656131: Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Fluzoparib, Fluzoparib+Camrelizumab | wang shusen | Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer | 03/25 | 12/26 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
SMA-BC-002, NCT05978648: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy |
|
|
| Recruiting | 2 | 116 | RoW | Trilaciclib, COSELA®, G1T28, Epirubicin, Cyclophosphamide, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab | wang shusen | Breast Neoplasms | 12/26 | 12/27 | | |
| Recruiting | 1 | 40 | RoW | TQB3728 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/21 | 05/22 | | |
| Recruiting | 1 | 70 | RoW | TQB3915 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 06/23 | 06/24 | | |
NCT06381050: The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SHR-7631 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 04/26 | 04/27 | | |
NCT05414136: Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 |
|
|
| Active, not recruiting | 1 | 37 | RoW | BAT1006, Recombinant humanized anti-HER2 monoclonal antibody for injection | Bio-Thera Solutions | Advanced Solid Tumor | 08/24 | 03/25 | | |
| Active, not recruiting | 1 | 164 | RoW | TQB3823 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor | 02/25 | 10/25 | | |
NCT05848466: Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients |
|
|
| Recruiting | 1 | 109 | RoW | BAT8010 for Injection | Bio-Thera Solutions | Advanced or Metastatic Solid Tumors | 05/25 | 07/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT03543059: A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients |
|
|
| Not yet recruiting | N/A | 2000 | RoW | GnRH analogue | Sun Yat-sen University | Breast Cancer | 06/21 | 06/23 | | |
NCT03543072: A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer Patients |
|
|
| Not yet recruiting | N/A | 2000 | RoW | Bisphosphonates | Sun Yat-sen University | Breast Cancer | 06/21 | 06/23 | | |
NCT06373744: Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients |
|
|
| Completed | N/A | 597 | RoW | cyclophosphamide , methotrexate , vinorelbine ,capecitabine | Sun Yat-sen University | Breast Cancer | 01/24 | 01/24 | | |
